Webinar: What’s Next for Biosimilars? History, Current Status and Future Expectations

• An overview of biosimilar focused analysis and insight from FirstWord, including reports and proprietary news and opinion via FirstWord Pharma PLUS.
• Introduction to Biosimilar Index, FirstWord’s proprietary biosimilars intelligence service, including a summary of key deliverables, benefits and channels.
• Historical review of the biosimilars market, including a review of some key events in the biosimilars market – focusing on clinical, regulatory, commercial and legal dynamics – and what experts think.
• Current market snapshot in terms of clinical trials activity, regulatory approvals, market performance, and key controversies e.g. extrapolation, interchangeability, legal challenges
• Future expectations, including a review of some key market catalysts over the next few years and what experts from a selected stakeholder group – payers – believe are the critical uncertainties that still remain.

This webinar is one of the many information sources you have access to when purchasing access to FirstWord’s Biosimilar Index.

FirstWord's Biosimilar Index is a comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Request a demo today

Biosimilar Index now includes over 525 biosimilar and NCB programmes and is segmented by developing company,  reference molecule, market status and therapeutic class, making it one of the most detailed biosimilar market tracking tools available today.

Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.

Biosimilar Index provides a collection of key journal articles, news stories, key regulatory developments, licensing availability and partnering information for all key programmes. All information is sorted in an easy-to-search tab of the datafile with links to source information.

Request a demo today

Podcast: Interview with Dr Paul Calvo, IP and Legal Expert